概括
硫芬拉改善了冠状动脉旁路移植后的血小板功能和存活率. 该药物减少了血小板激活和破坏,与改善的运动耐受性和减少心肌缺血相关.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在接受冠状动脉旁路移植 (CABG) 的患者中观察到血小板激活和血小板存活时间缩短.
- 血中β-血球蛋白和血小板因子4的升高水平表明CABG后血小板激活增加.
研究的目的:
- 评估硫芬拉对血小板功能和CABG后患者的存活率的影响.
- 研究血小板功能标志物与术后心肌缺血之间的关系.
主要方法:
- 血小板存活率和血β-血球蛋白/血小板因子4在44名CABG前后患者中进行了测量.
- 随机分配患者接受硫芬拉 (800毫克/天) 或术后安慰剂.
- 进行了术后运动测试.
主要成果:
- 在手术前,血小板存活率降低,β-血球蛋白/血小板因子4升高.
- 在术后,血小板功能指数趋向于正常,在硫芬拉组显着如此.
- 硫芬拉治疗导致血小板存活率显著改善,血蛋白水平降低.
结论:
- 硫芬拉有效地减少了血小板激活,并抑制了CABG后的血小板破坏.
- 在CABG后使用硫芬拉改善了血小板功能,与更好的运动耐受性相关.
- 血小板功能异常与术后心肌缺血有关.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...


